Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
MAGENTA: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to tes…
Relapsed Refractory Multiple Myeloma (RRMM)
Estimated
~$10 – $6,250
Massachusetts General HospitalNCT07032714
Phase 2
A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma
This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple…
Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma
Estimated
~$10 – $6,250
Massachusetts General HospitalNCT06832865
Phase 3
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other …
Relapsed Refractory Multiple Myeloma (RRMM)
Estimated
~$10 – $8,750
Regeneron PharmaceuticalsNCT05730036
Phase 2
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
Estimated
~$10 – $6,250
M.D. Anderson Cancer CenterNCT07382739